Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death

被引：1
作者：
Williams, Mark D. [1 ]
Janes, Jonathan M. [1 ]
Nelson, David R. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
CRITICAL CARE | 2006年 / 10卷 / 05期
关键词：
Severe Sepsis; Random Effect Model; Fixed Effect Model; Patient Level Data; Drotrecogin Alfa;
D O I：
10.1186/cc5062
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页数：2
相关论文
共 3 条
  • [1] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, E
    Laterre, P
    Garg, R
    Levy, H
    Talwar, D
    Trzaskoma, BL
    Francois, B
    Guy, JS
    Bruckmann, M
    Rea-Neto, A
    Rossaint, R
    Perrotin, D
    Sablotzki, A
    Arkins, N
    Utterback, BG
    Macias, WL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) : 1332 - 1341
  • [2] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [3] Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
    Friedrich, Jan O.
    Adhikari, Neill K. J.
    Meade, Maureen O.
    [J]. CRITICAL CARE, 2006, 10 (03)
1